Article

In vivo imaging of the pharmacodynamics and pharmacokinetics of lithium.

Department of Psychiatry and Behavioral Sciences, Emory Center for Positron Emission Tomography, Atlanta, Ga, USA.
The Journal of Clinical Psychiatry (Impact Factor: 5.14). 02/2000; 61 Suppl 9:41-6.
Source: PubMed

ABSTRACT The therapeutic efficacy of lithium for the long-term management of bipolar disorder is well recognized, along with the risk of lithium-induced toxicity. The author describes the current findings of in vivo functional neuroimaging techniques with respect to the pharmacokinetics and pharmacodynamics of lithium and their future potential to elucidate the drug distribution and neural mechanisms that produce its therapeutic effects. Brain Li nuclear magnetic resonance spectroscopy findings have disassociated postdose brain and blood lithium concentrations and suggest a pharmacokinetic basis for lithium response and nonresponse. The application of in vivo synaptic activity and neurochemical imaging is providing new knowledge related to the distributed neural activity associated with lithium response and is contributing to the critical human testing of neuroprotective and signal transduction models of lithium's therapeutic effects.

0 Followers
 · 
69 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Psychiatric diseases, including schizophrenia, bipolar disorder and major depression, are projected to lead global disease burden within the next decade. Pharmacotherapy, the primary - albeit often ineffective - treatment method, has remained largely unchanged over the past 50 years, highlighting the need for novel target discovery and improved mechanism-based treatments. Here, we examined in wild type mice the impact of chronic, systemic treatment with Compound 60 (Cpd-60), a slow-binding, benzamide-based inhibitor of the class I histone deacetylase (HDAC) family members, HDAC1 and HDAC2, in mood-related behavioral assays responsive to clinically effective drugs. Cpd-60 treatment for one week was associated with attenuated locomotor activity following acute amphetamine challenge. Further, treated mice demonstrated decreased immobility in the forced swim test. These changes are consistent with established effects of clinical mood stabilizers and antidepressants, respectively. Whole-genome expression profiling of specific brain regions (prefrontal cortex, nucleus accumbens, hippocampus) from mice treated with Cpd-60 identified gene expression changes, including a small subset of transcripts that significantly overlapped those previously reported in lithium-treated mice. HDAC inhibition in brain was confirmed by increased histone acetylation both globally and, using chromatin immunoprecipitation, at the promoter regions of upregulated transcripts, a finding consistent with in vivo engagement of HDAC targets. In contrast, treatment with suberoylanilide hydroxamic acid (SAHA), a non-selective fast-binding, hydroxamic acid HDAC 1/2/3/6 inhibitor, was sufficient to increase histone acetylation in brain, but did not alter mood-related behaviors and had dissimilar transcriptional regulatory effects compared to Cpd-60. These results provide evidence that selective inhibition of HDAC1 and HDAC2 in brain may provide an epigenetic-based target for developing improved treatments for mood disorders and other brain disorders with altered chromatin-mediated neuroplasticity.
    PLoS ONE 08/2013; 8(8):e71323. DOI:10.1371/journal.pone.0071323 · 3.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Bipolar disorder (BD) is a prevalent and disabling condition, often comorbid with other medical and psychiatric conditions and frequently misdiagnosed. International treatment guidelines for BD recommend the use of mood stabilizers - either in monotherapy or in association - as the gold standard in both acute and long-term therapy. Commonly used in the clinical practice of BD, mood stabilizers have represented an evolving field over the last few years. The concept of stabilization, in fact, has been stressed as the ultimate objective of the treatment of BD, given the chronic and recurrent nature of the illness, which accounts for its significant levels of impairment and disability. To date, different compounds are included within the broad class of mood stabilizers, with lithium, anticonvulsants and, more recently, atypical antipsychotics being the most representative agents. This article is aimed at providing an updated review of the available literature in relation to the role of mood stabilizers in BD, with particular emphasis on their mechanism of action, main clinical aspects and specific use in the different phases of BD treatment, according to the most recently published international treatment guidelines.
    Expert Review of Neurotherapeutics 01/2011; 11(1):85-99. DOI:10.1586/ern.10.181 · 2.83 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Lithium has been a medication used in psychiatry for more than 50 years and its efficacy has been established in the treatment of mood disorders. The use of lithium is limited due to its narrow therapeutic range and toxicity. Its persistent neurological secondary effects caught clinical attention in the 80s and were described by Adityanjee under the acronym SILENT (Syndrome of Lithium-effectuated Neurotoxicity). Objective: To discuss the clinical aspects of lithium toxicity and to increase physicians' awareness of this subject. Method: Narrative review based on the available literature. Results and Conclusion: More than 90% of individuals treated with lithium experience some side effect. Neurological sequelae include persistent cerebellar dysfunction, oculomotor abnormalities and peripheral neuropathy. It is important for physicians to recognize these symptoms and it becomes necessary to develop strategies like the use of stricter criteria for starting lithium to prevent acute intoxication, and the rigorous monitoring of serum levels during treatment.
    09/2008; 37(3):418-427.

Preview

Download
0 Downloads
Available from